Dedicated to fighting sepsis.
In the Spotlight
Septest shortlisted for Medilink Startup Award.
Septest has been shortlisted in the startup category at the Medilink Healthcare Business Awards 2024.
This category highlights the efforts of newly established companies in the healthcare sector that show a promising future.
Septest wins the TBAT Innovation Challenge.
Septest has won the TBAT innovation challenge. Septest not only secured the judges vote but also won the audience winner vote.
Co-founder Kelly pitched at the packed showcase event alongside the nine other finalists to claim the top prize package provided by TBAT and its industry partners worth over £50,000.
Septest Completes Herts Healthcare Accelerator.
Septest has completed the 2023 hearts healthcare accelerator.
The programme provided access to a range of experts from across various fields including life sciences, technology, design, business, and law to enable the development of innovations and early stage research.
About Us
Septest is on a mission to save lives and transform the journey of sepsis patients worldwide.
Founded by a sepsis survivor and diagnostic specialist, Septest has partnered with prominent sepsis experts and global organisations to produce a breakthrough point-of-need test for sepsis that can be implemented in any healthcare setting, in any part of the world.
Global Burden
Sepsis is a life-threatening illness caused by the body's response to an infection, resulting in systemic inflammation and organ dysfunction. It can affect anybody, from infants to the elderly, and progresses rapidly if not diagnosed and treated promptly.
Recognised as a global health crisis, sepsis affects an estimated 48.9 million people annually resulting in over 11 million deaths worldwide. In addition to the human toll, sepsis has a significant economic impact, with healthcare costs estimated to be in the billions of dollars every year.
Diagnostic Need
Early diagnosis of sepsis is critical, with every hour delay in treatment increasing the risk of death by 8-10%. Despite this urgency, current diagnostic methods are often time-consuming, expensive, and unavailable at the point-of-need. Septest's TRISEP test intends to bridge this gap by providing a simple, low-cost solution that integrates seamlessly into any healthcare setting, ensuring timely and effective treatment for sepsis patients worldwide.
Antimicrobial Resistance
The overuse of antibiotics in cases of non-bacterial sepsis has contributed to the rise of antimicrobial resistance (AMR), posing a significant challenge to sepsis management. This not only puts a strain on healthcare budgets, but it also makes it increasingly difficult to treat infections effectively. Septest seeks to tackle sepsis and AMR collectively by providing healthcare professionals with the tool they need to accurately diagnose sepsis and only prescribe antimicrobials when necessary.
Diagnostic Integration
Hospital Settings
The TRISEP test has been designed to confirm emergency treatment options following clinical assessment in suspected sepsis cases.
General Practice
The TRISEP test is well suited for use in GP practices to rapidly rule out viruses and other types of infection.
Community Setting
The TRISEP test may be performed by community health care providers such as pharmacists and at local healthcare clinics.
Our Focus
We are determined to see our technology in the hands of those who are fighting sepsis on the front lines.
Our ultra-accessible point-of-need test has been specifically designed to reduce normal barriers to diagnostic access, especially in LMIC's.
By implementing the TRISEP test, we believe we can reduce delays to diagnosis, treatment and, most importantly, save lives.
Sepsis Charity Information
Further information regarding sepsis and available support can be found by visiting the following registered sepsis charities.
Contact Us
For partnership opportunities, or to learn more about our revolutionary TRISEP test, please contact us using the form below.
© 2024 Septest Limited. All rights reserved.
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.
We need your consent to load the translations
We use a third-party service to translate the website content that may collect data about your activity. Please review the details and accept the service to view the translations.